Literature DB >> 21791869

Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. - Subanalysis of the J-RHYTHM Registry-.

.   

Abstract

BACKGROUND: Determinants of warfarin use and anticoagulation levels in atrial fibrillation (AF) patients have not been clarified thoroughly. METHODS AND
RESULTS: A total of 6,324 patients with non-valvular AF and congestive heart failure, hypertension, age, diabetes, prior stroke (CHADS₂) score ≥ 1 were used to investigate determinants of warfarin use, and 6,932 patients with AF receiving warfarin were used to investigate determinants of international normalized ratio (INR) of prothrombin time. Target INR levels for non-valvular AF patients were 1.6-2.6 for patients aged ≥ 70 years and 2-3 for patients aged < 70 years. Those for patients with valvular AF were 2-3. Patients with non-valvular AF and CHADS₂ score ≥ 1 receiving warfarin (n = 5,614) more frequently had permanent AF, congestive heart failure, and stroke or transient ischemic attack (TIA), and had higher CHADS₂ scores than those not receiving warfarin. Determinants of warfarin use were age (≥ 60 years), AF type (persistent and permanent), and comorbidities (congestive heart failure, diabetes mellitus, and prior stroke or TIA). Use of antiplatelet drugs was a negative determinant of warfarin use. Only 53% of patients met the target INR levels. Determinants for the meeting of the target INR level (vs. lower INR level) were age (≥ 60 years), permanent AF, hypertension, and prior stroke or TIA. Use of antiplatelet drugs was a negative determinant of the INR level.
CONCLUSIONS: Currently in Japan, adherence to the guidelines regarding anticoagulation therapy is limited (UMIN Clinical Trials Registry UMIN000001569).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791869     DOI: 10.1253/circj.cj-11-0427

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  4 in total

1.  Prediction of left atrial thrombi in patients with atrial tachyarrhythmias during warfarin administration: retrospective study in Hyogo College of Medicine.

Authors:  Hideyuki Kishima; Takanao Mine; Takeshi Kodani; Tohru Masuyama
Journal:  Heart Vessels       Date:  2015-05       Impact factor: 2.037

2.  Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.

Authors:  Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Manesh R Patel; Frank E Harrell; Daniel E Singer; Richard C Becker; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

3.  Rationale and design of ASSAF-K (A study of the safety and efficacy of anticoagulant therapy in the treatment of atrial fibrillation in Kanagawa).

Authors:  Yutaka Hatori; Hiroyuki Sakai; Tomoyuki Kunishima; Nobuo Hatori; Lin Chen; Tomoaki Ishigami; Naoki Satoh
Journal:  J Arrhythm       Date:  2016-08-23

4.  Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hirotsugu Atarashi; Hiroshi Inoue; Ken Okumura; Takeshi Yamashita; Toshiaki Otsuka; Hirofumi Tomita; Hideki Origasa
Journal:  J Am Heart Assoc       Date:  2016-09-12       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.